Anti-angiogenic treatment strategies for the therapy of endometriosis. - Wikidata - wikimedia - TriplyDB

Anti-angiogenic treatment strategies for the therapy of endometriosis.

Anti-angiogenic treatment strategies for the therapy of endometriosis.

http://www.wikidata.org/entity/Q34283036

about

Defining future directions for endometriosis research: workshop report from the 2011 World Congress of Endometriosis In Montpellier, France Pathogenesis of Endometriosis: Roles of Retinoids and Inflammatory Pathways The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy Endometriosis: Survey of Current Diagnostic and Therapeutic Options and Latest Research Work.An update on the pharmacological management of endometriosis.Consensus on current management of endometriosis.Peripheral changes in endometriosis-associated pain.Expression of vascular endothelial growth factor C and anti-angiogenesis therapy in endometriosis.Vascular endothelial growth factor receptor-2 inhibitor cediranib causes regression of endometriotic lesions in a rat model Endometriosis: alternative methods of medical treatment.MiR-199a inhibits the angiogenic potential of endometrial stromal cells under hypoxia by targeting HIF-1α/VEGF pathway.Inhibition of Hyaluronic Acid Synthesis Suppresses Angiogenesis in Developing Endometriotic Lesions.IL-17A Contributes to the Pathogenesis of Endometriosis by Triggering Proinflammatory Cytokines and Angiogenic Growth Factors Efficacy of Anti-VEGF/VEGFR Agents on Animal Models of Endometriosis: A Systematic Review and Meta-Analysis.Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model.NME1 suppression of endometrial stromal cells promotes angiogenesis in the endometriotic milieu via stimulating the secretion of IL-8 and VEGF.Chronic effects of an anti-angiogenic thrombospondin-1 mimetic peptide, ABT-898, on female mouse reproductive outcomes.Luminal epithelium in endometrial fragments affects their vascularization, growth and morphological development into endometriosis-like lesions in mice.The motile and invasive capacity of human endometrial stromal cells: implications for normal and impaired reproductive function.Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain.MAP kinases and the inflammatory signaling cascade as targets for the treatment of endometriosis?An overview of early drug development for endometriosis.Resveratrol is a potent inhibitor of vascularization and cell proliferation in experimental endometriosis.Role of the protein kinase BRAF in the pathogenesis of endometriosis.Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis.Adenoviral vector encoding soluble Flt-1 engineered human endometrial mesenchymal stem cells effectively regress endometriotic lesions in NOD/SCID mice.Ginsenoside Rg3 inhibits angiogenesis in a rat model of endometriosis through the VEGFR-2-mediated PI3K/Akt/mTOR signaling pathway.Guizhi fuling capsule, an ancient Chinese formula, attenuates endometriosis in rats via induction of apoptosis.Combination therapy with telmisartan and parecoxib induces regression of endometriotic lesions.A potential novel treatment strategy: inhibition of angiogenesis and inflammation by resveratrol for regression of endometriosis in an experimental rat model.Comparison of efficacy of bromocriptine and cabergoline to GnRH agonist in a rat endometriosis model.Regression of experimental endometriotic implants in a rat model with the angiotensin II receptor blocker losartan.Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-γ by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions.Efficacy, safety and recurrence of new progestins and selective progesterone receptor modulator for the treatment of endometriosis: a comparison study in mice.Shaofu Zhuyu Decoction Regresses Endometriotic Lesions in a Rat Model.Anti-Angiogenic Alternative and Complementary Medicines for the Treatment of Endometriosis: A Review of Potential Molecular Mechanisms A possible role for fumagillin in cellular damage during host infection by Aspergillus fumigatus Monitoring antiangiogenesis of bevacizumab in zebrafish

P2860

Q26823337-CCBBFBE8-1826-4E1A-912C-9FB0C887CEE3 Q28083420-0E685381-FB24-4259-B5A7-5DFEA5E5AE05 Q29040166-7D8009F0-7AE4-406A-84D5-545F97A02B07 Q34129655-F4F30851-3611-4314-93E5-C5D9D04671B0 Q34324798-86891108-0E22-4929-B056-7E417C50C821 Q34335288-154383DF-1262-48E8-9E56-C72DAB08E3BA Q34421299-F58210A0-6236-46AF-ADC0-401349812467 Q34733388-4CA1C9A9-D7CC-433B-9203-65F9AD211ADC Q35406146-8002D7FB-E94F-4624-9E10-A509ADD4200D Q35668144-FDE51D84-FCCF-413D-B5B6-4B292ECA9096 Q35853946-DEBDB5B7-2939-463F-BB1C-2C095A4DD900 Q35971408-BD18916F-0DAC-4C67-8C7E-09A86F8F0D49 Q36031565-044B0BCA-EC1F-42C7-AA57-1162856E162E Q36195128-5463EC9F-3042-44D0-8183-618B8A12CECF Q36679982-2F36D637-349E-4F0B-91F6-08A7969E95EF Q37117375-948F1037-5C6B-4113-9F21-E8773254355A Q37228804-03AFDAD0-BE52-486D-A33D-1B1359CA2681 Q37240221-721148B8-28F4-4B15-9683-187B1124EF6F Q37566114-8C0B8DF2-9331-421B-B44C-3E2ED82EB51F Q38119393-55467943-4D04-467F-B7C2-781634217B82 Q38315212-E3CFEE51-2968-4F9D-9557-453C8D070042 Q38590189-FCADF847-B31E-477E-BFB1-3DFCA12CD5C7 Q38653393-37443E20-F266-4078-96F5-D58C81DCA215 Q39464111-7B25A20E-2B5E-4901-AAA5-E88BEC8C7211 Q39844384-C279ADF4-67FB-429E-BBC1-DEAD92DC32CE Q40743672-0151E442-F422-4F81-A9C6-6E9BA233A631 Q40846016-DF8C3642-9D10-4265-9DD3-BE34EF396408 Q45375172-C1BDBC66-EBAB-4973-9ED4-5D4FAE1B5515 Q47668588-B66EE7DA-061F-45C3-8415-B37EBF8BCBF5 Q48370696-38B14115-1822-4DA8-97C5-1605F2908A7E Q51037349-79E5688A-CE97-4EF3-B0CB-422BFA9ADF31 Q51103462-0FB2C5C7-C3EC-4FF8-9928-69C2D07C5F36 Q51107745-685429D6-2CEC-4F90-B761-DFD43F4CA3A1 Q51157373-FE264157-02AD-4AFC-AA86-6174382134D6 Q52609438-BB5E6FB7-70B4-48AF-97EB-CC01B2A7E1AC Q55077369-32D4C5B6-C68C-4408-9EB1-13DA0E279AC1 Q58592397-60DDF24D-CCFD-4FAC-846C-65485E9317D6 Q58697378-0A7C3FCB-24A6-4047-B704-32EDD2C27CEB Q58799244-4769B662-8622-4176-AC64-CCAD0275455C

P2860

Anti-angiogenic treatment strategies for the therapy of endometriosis.

http://www.wikidata.org/entity/Q34283036

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Anti-angiogenic treatment strategies for the therapy of endometriosis.

@ast

Anti-angiogenic treatment strategies for the therapy of endometriosis.

@en

Anti-angiogenic treatment strategies for the therapy of endometriosis.

@nl

type

label

Anti-angiogenic treatment strategies for the therapy of endometriosis.

@ast

Anti-angiogenic treatment strategies for the therapy of endometriosis.

@en

Anti-angiogenic treatment strategies for the therapy of endometriosis.

@nl

prefLabel

Anti-angiogenic treatment strategies for the therapy of endometriosis.

@ast

Anti-angiogenic treatment strategies for the therapy of endometriosis.

@en

Anti-angiogenic treatment strategies for the therapy of endometriosis.

@nl

P1433

Q34283036-746906C5-8F82-4F0A-AAA7-B3246D82152B

P1476

Q34283036-BD9913CA-7AC7-4CAB-BDBA-A5464F299AC9

P2093

Q34283036-0C4041DB-3269-472E-8D9F-2C43152BBAF9

Q34283036-CC0AE10D-212F-4BAC-B81A-1E1527F6890C

P2860

Q34283036-01233C9E-823F-4B24-97FF-CB53B2E5ACDD

Q34283036-03DB8BFF-AA82-4B7D-B561-A0679C12BE4C

Q34283036-08B3ECA4-DB32-4D60-9EA9-339DFDF6B0D1

Q34283036-09746265-6E29-4F94-ACF9-BCEC546865C5

Q34283036-09B3D4AB-2463-4C34-8600-81F63D316388

Q34283036-0AD8B115-DB23-4488-8AFB-8CC2B6845702

Q34283036-0B4E5A2C-5DDA-434C-9B9D-726DB0B82B64

Q34283036-0B5F0B19-9F51-4C14-90B2-576B1156CDC2

Q34283036-0FDA5486-DEB4-4CCE-8F89-BBBF74B4ACDA

Q34283036-0FF6BE9B-B0C2-4454-A065-E562E9CCEE71

P304

Q34283036-6446E041-3BF7-4CF3-A93F-55AEE2839A47

P31

Q34283036-305FD44B-A6B4-4367-9137-F653D964CA06

P356

Q34283036-633A9D7A-7BC9-4C69-A8D4-A0533C70EA2B

P433

Q34283036-1440497C-E122-4466-A1BF-08F30D41252C

P478

Q34283036-E1FC3647-F625-4260-A877-8683B1D85A40

P577

Q34283036-546AF6D6-FC0C-482A-9A71-A1CB5A5422EB

P698

Q34283036-B83A8A33-3BE7-43D7-81CA-FB6A2AE5C0CF

P921

Q34283036-2A3C9887-F52E-403F-872B-AE18BD3580F0

P356

P1433

Human Reproduction Update

P1476

Anti-angiogenic treatment strategies for the therapy of endometriosis.

@en

P2093

M D Menger

http://www.w3.org/2001/XMLSchema#string

M W Laschke

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor

Endometriosis and infertility

The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases

EGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment

Chronic pelvic pain and endometriosis: translational evidence of the relationship and implications

Phytoestrogen biological actions on Mammalian reproductive system and cancer growth

An orally delivered small-molecule formulation with antiangiogenic and anticancer activity

Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy

P304

682-702

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/HUMUPD/DMS026

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22718320

http://www.w3.org/2001/XMLSchema#string

P921